John Zalcberg, PhD | Authors

Articles

Dr. John Zalcberg on Regorafenib in Refractory Advanced Oesophago-Gastric Cancer Patients

November 11, 2015

John Zalcberg, PhD, medical oncologist, Peter MacCallum Cancer Centre, Melbourne, Australia, talks about the poor prognosis of refractory advanced oesophago-gastric cancer (AOGC) patients and how regorafenib could benefit those patients.